Tandem Diabetes Care Q2 Adj EPS $(0.30) Beats $(0.53) Estimate, Sales $195.92M Miss $197.64M Estimate
Portfolio Pulse from saritha@benzinga.com
Tandem Diabetes Care reported Q2 losses of $(0.30) per share, beating the analyst consensus estimate of $(0.53) by 43.4%. However, the company's quarterly sales of $195.92 million missed the analyst consensus estimate of $197.64 million by 0.87%.
August 04, 2023 | 2:21 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Tandem Diabetes Care's Q2 earnings beat estimates but sales fell short, which could lead to mixed market reactions.
While the company beat earnings estimates, which is generally a positive signal to investors, it missed on sales, which could be a concern. This mixed result may lead to uncertainty in the market, potentially causing volatility in the stock's price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100